Results

• All
• Video
• Audio
• Images

• Most recent
• Filter by category

1–5 of 5 results for aflibercept 8 mg

• 

  Expert Panel: Faricimab and Aflibercept 8 mg in AMD

  John T. Thompson, MD

  Andrew A. Moshfeghi, MD, MBA, FASRS

  Manjot K Gill, MD, FASRS

  Christina Y Weng, MD, MBA, FASRS

  Ferhina S Ali, MD, MPH

  Ian Pearce, MB ChB BSc FRCOPHTH

  Annual Meeting Talks

  2024

• 

  Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy

  Judy E. Kim, MD, FASRS

  Chirag D. Jhaveri, MD, FASRS

  Michael S. Ip, MD

  Arshad M. Khanani, MD, MA, FASRS

  Jordana G Fein, MD, MS

  Dennis M. Marcus, MD

  Diana V Do, MD, FASRS

  Annual Meeting Talks

  2024

• 

  PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration

  David T.W. Wong, MD, FRCS(C), FASRS

  Updates from the Field

  2025

• 

  Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study

  Eric W Schneider, MD

  Updates from the Field

  2025

• 

  Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial

  Diana V Do, MD, FASRS

  Updates from the Field

  2024